초록

The invention provides methods for treating Aβ peptide related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 modulator to a patient in need thereof.

대표청구항 ▼

1. A method to identify a candidate modulator which reduces the accumulation of Aβ peptide levels in the brain, wherein the accumulation of Aβ peptide levels is reduced as compared to a control modulator, comprising assaying for the ability of a candidate modulator to inhibit Casein Kinase 1 (“CK1”)

1. A method to identify a candidate modulator which reduces the accumulation of Aβ peptide levels in the brain, wherein the accumulation of Aβ peptide levels is reduced as compared to a control modulator, comprising assaying for the ability of a candidate modulator to inhibit Casein Kinase 1 (“CK1”) activity by: a) providing a biological sample comprising or expressing a CK1 polypeptide;b) contacting said biological sample with a candidate modulator and measuring the phosphorylation activity and/or gene expression of CK1 in the biological sample after the sample has been contacted with the candidate modulator;c) contacting said biological sample with a control modulator wherein the control modulator is known to modulate the activity of CK1 and/or gene expression of CK1, and measuring the phosphorylation activity and/or gene expression of CK1 in the biological sample after the sample has been contacted with the control modulator;d) comparing CK1 phosphorylation activity and/or gene expression between the candidate and control modulators;e) selecting a candidate modulator for further testing based upon its ability to decrease the phosphorylation activity of CK1 and/or gene expression of CK1, and wherein the candidate modulator decreases the phosphorylation activity and/or gene expression of CK1 relative to the control modulator;f) testing the candidate modulator in an animal model of an Aβ related disorder, wherein the candidate modulator is administered in said animal model and CK1phosphorylation activity and/or gene expression in the brain is measured after administration and compared to a control modulator in an animal model of an Aβ related disorder; andg) identifying a candidate modulator based upon its ability to decrease CK1phosphorylation activity and/or gene expression and reduce the accumulation of AB peptide in the brain of in the animal model. 2. The method according to claim 1 wherein said Aβ related disorder is Alzheimer's disease. 3. The method according to claim 1 wherein said method further comprises assaying for the ability of the candidate modulator to reduce the levels of Aβ peptide in brain tissue samples of animal models of an Aβ related disorder and/or in clinical studies with subjects with an Aβ related disorder comprising: 1) providing a biological sample comprising or expressing a Aβ peptide;2) contacting said biological sample with the candidate modulator to be screened and measuring the levels of Aβ peptide in the biological sample after the sample has been contacted with the candidate modulator;3) contacting said biological sample with a control modulator wherein the control modulator is known to reduce the levels of Aβ peptide and measuring the levels of Aβ peptide in the biological sample after the sample has been contacted with the control modulator;4) comparing the levels of Aβ peptide between the candidate and control candidate modulators;5) selecting a candidate modulator based upon its ability to decrease levels of Aβ peptide, and wherein a candidate modulator decreases the level of Aβ peptide relative to the control modulator;6) testing a candidate modulator in an animal model and/or in a clinical study wherein the candidate modulator is administered in said animal model and levels of Aβ peptide are measured after administration and compared to a control; and7) identifying a potential candidate modulator based upon its ability to decrease levels of Aβ peptide in the animal model and/or clinical study. 4. A method of claim 1, wherein the CK1 is Casein Kinase 1ε (“CK1ε”).